Research programme: mTOR inhibitors - Valerio Therapeutics
Alternative Names: 44001; SCR 44001; TOP 201; TOP 216Latest Information Update: 08 Sep 2023
At a glance
- Originator BioImage
- Developer Valerio Therapeutics
- Class Small interfering RNA
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Sep 2014 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 10 Jul 2009 Preclinical development is ongoing Denmark